⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3838632 | 0.77 | MMP2 (0.35) | — | |
| SCHEMBL11834742 | 0.74 | LPL (0.42) | — | |
| SCHEMBL3840699 | 0.72 | — | — | |
| SCHEMBL3844871 | 0.72 | — | — | |
| SCHEMBL189186 | 0.67 | — | — | |
| SCHEMBL11247173 | 0.65 | — | — | |
| SCHEMBL3837742 | 0.61 | — | — | |
| SCHEMBL3027928 | 0.61 | — | — | |
| SCHEMBL4788864 | 0.60 | — | — | |
| SCHEMBL7191487 | 0.59 | LPL (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2284157-A1 | Quinolines useful in treating cardiovascular disease | Wyeth (US) | 2011-02-16 | — | — | EP | disclosed |
| EP-1253152-B1 | METHOD OF CONVERTING FUNCTIONAL GROUP THROUGH HALOGEN-METAL EXCHANGE REACTION | BANYU PHARMA CO LTD (JP) | 2009-11-04 | — | — | EP | disclosed |
| US-7576215-B2 | Quinolines and pharmaceutical compositions thereof | WYETH (US) | 2009-08-18 | — | — | US | disclosed |
| US-7439535-B2 | Process for exchanging functional groups by halogen-metal exchange reaction | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-10-21 | — | — | US | disclosed |
| EP-1692111-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | Wyeth, A Corporation of the State of Delaware (US) | 2006-08-23 | — | — | EP | disclosed |
| US-6946559-B2 | Replacing a halogen atom with an electrophilic group (e.g., a formyl group) using either a mixture of an organomagnesium halide and an alkyllithium or a reaction product of the two, such as trialkylmagnesium lithium | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-09-20 | — | — | US | disclosed |
| US-20050156336-A1 | Process for exchanging functional groups by halogen-metal exchange reaction | MSD K.K. (JP) | 2005-07-21 | — | — | US | disclosed |
| WO-2005058834-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | WYETH (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | WYETH (US) | 2005-06-16 | — | — | US | disclosed |
| US-20030130511-A1 | Method of converting functional group through halogen-metal exchange reaction | MSD K.K. (JP) | 2003-07-10 | — | — | US | disclosed |
| EP-1253152-A1 | METHOD OF CONVERTING FUNCTIONAL GROUP THROUGH HALOGEN-METAL EXCHANGE REACTION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-10-30 | — | — | EP | disclosed |
| US-4316905-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-02-23 | — | — | US | disclosed |